Healthcare Industry News: Corixa
News Release - July 17, 2007
Biomira appoints industry veteran as Chief Operating OfficerEDMONTON, July 17 (HSMN NewsFeed) - Biomira Inc. (Nasdaq: BIOM ; TSX: BRA ) today announced the appointment of Gary Christianson to the newly created position of Chief Operating Officer. Mr. Christianson brings to Biomira more than 20 years of operational expertise in diverse areas, including technical development, manufacturing of pharmaceutical products, facilities design and management, and personnel development.
"Gary's extensive operational expertise will be an important asset as we work to realize the potential of our expanding pipeline," said Dr. Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "Biomira is responsible for all manufacturing activities for our Phase 3 vaccine, Stimuvax®, including process scale-up for commercialization, and Gary has the background to lead this effort. With PX-12 in Phase 2, PX-478 expected to enter Phase 1 this quarter, and an Investigational New Drug application planned for PX-866 by year's end, there are also multiple technical development and manufacturing activities for our small molecule pipeline. In addition, I expect that Gary will play a significant role in developing strategies to integrate our multi-site activities and to maximize our efficiency, productivity and capabilities. We are pleased to welcome him to the Biomira team."
Mr. Christianson said, "I am very excited to join Biomira and believe that its development pipeline holds numerous opportunities to make a difference in the lives of cancer patients. I look forward to working with the rest of the Biomira management team to create value for patients and for the Company's investors."
Mr. Christianson was, most recently, Site Director for GlaxoSmithKline's (GSK) Biologics Unit in Hamilton, Montana. In this position, he oversaw staffing and planning for a 250-person facility that manufactured a key component of several GSK vaccines. Previously, he spent six years as Vice President, Technical Operations at Corixa Corp., including two years as a General Manager. In addition to facility and personnel responsibilities at Corixa, Mr. Christianson also oversaw production of Bexxar® (Tositumomab and Iodine I 131 Tositumomab), an approved cancer therapy. From 1987 to 1999, Mr. Christianson held positions of increasing responsibility at RIBI ImmunoChem Research, rising to Director, Production and Engineering. He received a B.S. in Mechanical Engineering Technology from Montana State University and is a Licensed and Board Certified Professional Engineer. He is a member of numerous professional organizations, including the International Society for Pharmaceutical Engineers and the Parenteral Drug Association.
Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.
This press release contains forward looking statements, including, without limitation, statements related to drug candidates in Biomira's pipeline; future clinical development plans; the details of the clinical trials; and the anticipated manufacturing activities for Stimuvax and other Biomira product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, the anticipated manufacturing activities for Biomira product candidates, and the possibility of future commercialization of any Biomira product. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.